ifosfamide and Germinoblastoma studies

Research Excerpts

Excerpt	Relevance	Reference
"This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients."	9.51	Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. ( André, M; Berriolo-Riedinger, A; Borel, C; Brice, P; Edeline, V; Feugier, P; Gac, AC; Gastinne, T; Ghesquières, H; Guidez, S; Le Bras, F; Morschhauser, F; Nicolas-Virelizier, E; Quittet, P; Ribrag, V; Stamatoullas, A; Vander Borght, T, 2022)
"Given the poor outcomes of relapsed aggressive lymphomas and preclinical data suggesting that ≥2·5 μmol/l concentrations of vorinostat synergize with both etoposide and platinums, we hypothesized that pulse high-dose vorinostat could safely augment the anti-tumour activity of (R)ICE [(rituximab), ifosphamide, carboplatin, etoposide] chemotherapy."	9.17	A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. ( Boyd, TE; Budde, LE; Chen, TL; Frayo, SL; Gooley, TA; Gopal, AK; Kammerer, BE; Knudsen, NL; Oliveira, GR; Pagel, JM; Press, OW; Roden, JE; Shustov, AR; Warr, TA; Zhang, MM, 2013)
"High-dose methotrexate is the standard of care for patients with newly diagnosed primary CNS lymphoma."	9.14	High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. ( Bamberg, M; Birnbaum, T; Fischer, L; Griesinger, F; Herrlinger, U; Hertenstein, B; Hundsberger, T; Jahnke, K; Kanz, L; Korfel, A; Leithäuser, M; Martus, P; Mergenthaler, HG; Nägele, T; Pietsch, T; Plasswilm, L; Rauch, M; Röth, A; Thiel, E; von Toll, T; Weller, M, 2010)
"The 4-day combination of dexamethasone, ifosfamide, cisplatin, and etoposide (DICE) is a salvage regimen for lymphoma."	9.11	A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. ( Abdi, E; Biagi, JJ; Dale, B; Falkson, C; Herbert, KE; Januszewicz, H; Leahy, M; Matthews, JP; Prince, HM; Richards, K; Seymour, JF; Smith, C; Wolf, M, 2005)
"To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate."	9.11	ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. ( Holte, H; Jerkeman, M; Kvaløy, S; Leppä, S, 2004)
"The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas."	9.09	Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. ( Balzarotti, M; Bertuzzi, A; Castagna, L; Magagnoli, M; Nozza, A; Santoro, A; Sarina, B; Sinnone, M; Siracusano, L; Timofeeva, I, 2001)
"One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i."	9.09	High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K, 2001)
"In this study we explored whether a standard chemotherapy regimen consisting of mitoguazone, ifosfamide, methotrexate and etoposide (MIME) combined with 5 micrograms/kg or 10 micrograms/kg G-CSF was capable of mobilizing peripheral blood progenitor cells (PBPC) in lymphoma patients."	9.09	Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. ( Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Rusten, LS, 2001)
"We have previously reported that combination chemotherapy based on the drugs cytarabine/platinum is effective in recurring lymphomas."	9.08	A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. ( Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W, 1995)
"Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma."	9.08	Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995)
"To evaluate the response to oral Etoposide when combined with mesna, ifosfamide, and mitoxantrone in patients with relapsed and/or refractory lymphoma."	9.07	A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. ( Cabanillas, F; Hagemeister, FB; Hill, D; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, JE; Sarris, AH; Swan, F; Younes, A, 1994)
"Ifosfamide is an alkylating agent with proven efficacy in the treatment of solid tumours and malignant lymphomas."	8.81	The role of ifosfamide in the treatment of relapsed and refractory lymphoma. ( Bredenfeld, H; Diehl, V; Engert, A; Reiser, M, 2001)
"Contemporary data of peripheral T-cell lymphoma (PTCL) and natural-killer/T-cell lymphoma (NKTL) patients treated with ifosfamide, carboplatin and etoposide (ICE) are limited."	8.12	Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy. ( Chan, EHL; Chan, JYS; Chang, EWY; Chee, YL; de Mel, S; Diong, C; Farid, M; Goh, AZK; Goh, YT; Grigoropoulos, NF; Jeyasekharan, A; Khoo, LP; Lee, J; Lee, YS; Lim, C; Lim, ST; Liu, X; Nagarajan, C; Poon, E; Poon, M; Quek, R; Somasundaram, N; Tan, D; Tang, T; Tao, M; Tay, T; Yang, VSW, 2022)
"In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)."	7.77	Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. ( Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T, 2011)
"We evaluated response, progression-free survival (PFS), overall survival (OS), relapse patterns and long-term toxicity of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO)."	7.75	Ifosfamide or trofosfamide in patients with intraocular lymphoma. ( Bechrakis, NE; Fischer, L; Jahnke, K; Korfel, A; Kraemer, DF; Thiel, E; Willerding, G, 2009)
"Two commonly used chemotherapy regimens for lymphoma salvage therapy were compared: ICE (ifosphamide, carboplatin and etoposide) +/- rituximab and IVE (ifosfamide, epirubicin and etoposide) +/- rituximab, for their efficacy in mobilising peripheral blood stem cells for autologous transplantation."	7.74	IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. ( Bishton, MJ; Fox, CP; Haynes, AP; McMillan, AK; Russell, NH, 2008)
"A three-drug combination of ifosfamide, epirubicin and etoposide (IEV) was used to treat 62 patients with relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL; n=51) or Hodgkin's disease (HD; n=11)."	7.71	Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. ( Alinari, L; Baccarani, M; Bonifazi, F; Gabriele, A; Molinari, AL; Salvucci, M; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zuffa, E, 2002)
"Thirty adult patients with relapsed or refractory malignant lymphoma underwent a Phase I-II trial of salvage chemotherapy combining methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI protocol)."	7.68	Salvage therapy with methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI) for recurrent or refractory lymphoma. ( Baume, D; Carde, P; Droz, JP; Gilles, E; Hayat, M; Moran, A; Ostronoff, M; Pico, JL; Zambon, E, 1990)
"Thirty-seven patients with malignant lymphoma were treated with mitoxantrone, ifosfamide, vindesine, and prednisolone."	7.68	Therapy with mitoxantrone, ifosfamide, vindesine, and prednisolone for malignant lymphoma with adjustable doses and timing of courses. ( Furukawa, Y; Hiyoshi, M; Im, T; Inoue, T; Kishida, T; Okuda, K; Park, K; Sasaki, A; Tatsumi, N; Yamane, T, 1991)
"Between 1983 and 1985, we conducted a phase II clinical trial using VP-16, ifosfamide, and cisplatin (VIP) in patients with refractory lymphoma."	7.67	Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. ( Greist, A; Hoffman, R; Kubilis, PS; Loehrer, PJ; Nichols, CR, 1988)
"Eighteen patients with high-grade malignant lymphoma were treated with ifosfamide-VP16213 combinations after failing to respond completely or after relapsing on CHOP-like therapy."	7.67	Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma. ( Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ, 1988)
"Twenty patients with refractory malignant lymphoma were treated with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) as salvage chemotherapy."	7.67	[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma]. ( Goto, S; Hotta, T; Ichikawa, A; Inoue, C; Murate, T; Nagura, E; Ninomiya, N; Ohnishi, K; Tsushita, K; Utsumi, M, 1989)
"The result of a combination consisting of ifosfamide and etoposide was evaluated in 57 patients suffering from non-Hodgkin's lymphoma (NHL) who had relapsed or were resistant to adriamycin-containing combinations."	7.67	Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma. ( Cavallin-Ståhl, E; Hagberg, H; Lind, J, 1986)
"Twenty patients with malignant lymphomas refractory to prior combination chemotherapy were treated with ifosfamide (40 mg/kg/day i."	7.66	Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy. ( Bremer, K; Niederle, N; Scheulen, ME; Seeber, S, 1983)
"Eighteen patients with advanced non-Hodgkin's lymphoma other than the diffuse histiocytic type were treated with a combination of adriamycin, vincristine, ifosfamide and prednisolone (AVIP)."	7.66	Combination chemotherapy of advanced non-Hodgkin's lymphoma with adriamycin, vincristine, ifosfamide and prednisolone (AVIP): a preliminary report. ( Hayashi, K; Kimura, I; Nishihara, R; Ohnoshi, T; Oka, A; Sando, Y; Sato, M; Tanaka, T; Ueoka, H; Yasuoka, M, 1982)
"Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed."	6.73	Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007)
"Ifosfamide is an active agent as part of combination therapy for patients with both indolent and aggressive relapsed lymphomas, and has also been used in high-dose therapy regimens followed by stem cell or bone marrow rescue."	6.40	The role of ifosfamide in the treatment of lymphomas. ( Hagemeister, FB, 1999)
"This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients."	5.51	Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. ( André, M; Berriolo-Riedinger, A; Borel, C; Brice, P; Edeline, V; Feugier, P; Gac, AC; Gastinne, T; Ghesquières, H; Guidez, S; Le Bras, F; Morschhauser, F; Nicolas-Virelizier, E; Quittet, P; Ribrag, V; Stamatoullas, A; Vander Borght, T, 2022)
"Eight patients had low-grade non-Hodgkin's lymphoma (NHL), 28 had high-grade NHL, and 11 patients had Hodgkin's disease."	5.28	Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. ( Anders, CH; Moritz, T; Nagel-Hiemke, M; Niederle, N; Nowrousian, MR; Schmidt, CG; Seeber, S, 1991)
"Given the poor outcomes of relapsed aggressive lymphomas and preclinical data suggesting that ≥2·5 μmol/l concentrations of vorinostat synergize with both etoposide and platinums, we hypothesized that pulse high-dose vorinostat could safely augment the anti-tumour activity of (R)ICE [(rituximab), ifosphamide, carboplatin, etoposide] chemotherapy."	5.17	A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. ( Boyd, TE; Budde, LE; Chen, TL; Frayo, SL; Gooley, TA; Gopal, AK; Kammerer, BE; Knudsen, NL; Oliveira, GR; Pagel, JM; Press, OW; Roden, JE; Shustov, AR; Warr, TA; Zhang, MM, 2013)
"High-dose methotrexate is the standard of care for patients with newly diagnosed primary CNS lymphoma."	5.14	High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. ( Bamberg, M; Birnbaum, T; Fischer, L; Griesinger, F; Herrlinger, U; Hertenstein, B; Hundsberger, T; Jahnke, K; Kanz, L; Korfel, A; Leithäuser, M; Martus, P; Mergenthaler, HG; Nägele, T; Pietsch, T; Plasswilm, L; Rauch, M; Röth, A; Thiel, E; von Toll, T; Weller, M, 2010)
"The 4-day combination of dexamethasone, ifosfamide, cisplatin, and etoposide (DICE) is a salvage regimen for lymphoma."	5.11	A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. ( Abdi, E; Biagi, JJ; Dale, B; Falkson, C; Herbert, KE; Januszewicz, H; Leahy, M; Matthews, JP; Prince, HM; Richards, K; Seymour, JF; Smith, C; Wolf, M, 2005)
"To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate."	5.11	ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. ( Holte, H; Jerkeman, M; Kvaløy, S; Leppä, S, 2004)
"One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i."	5.09	High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K, 2001)
"The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas."	5.09	Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. ( Balzarotti, M; Bertuzzi, A; Castagna, L; Magagnoli, M; Nozza, A; Santoro, A; Sarina, B; Sinnone, M; Siracusano, L; Timofeeva, I, 2001)
"Six cases with recurrent or refractory primary central nervous system lymphoma were treated with a new chemotherapeutic regimen "DeVIC (dexamethasone, VP16, ifosfamide, carboplatin)"."	5.09	[Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma]. ( Hatano, H; Hatano, N; Kajita, Y; Kinoshita, T; Takasu, S; Usui, T; Wakabayashi, T; Yoshida, J, 2000)
"In this study we explored whether a standard chemotherapy regimen consisting of mitoguazone, ifosfamide, methotrexate and etoposide (MIME) combined with 5 micrograms/kg or 10 micrograms/kg G-CSF was capable of mobilizing peripheral blood progenitor cells (PBPC) in lymphoma patients."	5.09	Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. ( Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Rusten, LS, 2001)
" Relapsing progressive lymphoma patients (n = 204; non-Hodgkin's lymphoma n = 166; Hodgkin's disease n = 38) were, after induction treatment with the DHAP-VIM (cisplatin, cytarabine, dexamethasone, etoposide, ifosfamide, methotrexate) regimen, randomly (2:1) assigned to the harvest of granulocyte-macrophage colony-stimulating factor-mobilized stem cells after the second DHAP course or autologous bone marrow cells before the second DHAP course."	5.09	Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. ( Croockewit, AJ; Fibbe, WE; Kingma, T; Uyl-de Groot, CA; van Agthoven, M; van Imhoff, GW; van Oers, MH; Vellenga, E; Verdonck, LF; Volkers, CP; Wijermans, PJ, 2001)
"We have previously reported that combination chemotherapy based on the drugs cytarabine/platinum is effective in recurring lymphomas."	5.08	A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. ( Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W, 1995)
"Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma."	5.08	Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995)
"To evaluate the response to oral Etoposide when combined with mesna, ifosfamide, and mitoxantrone in patients with relapsed and/or refractory lymphoma."	5.07	A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. ( Cabanillas, F; Hagemeister, FB; Hill, D; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, JE; Sarris, AH; Swan, F; Younes, A, 1994)
"Nine of the patients treated with ifosfamide developed congestive heart failure (17%; 95% Cl, 8% to 30%)."	5.07	High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. ( Bryant, G; Cunnion, RE; Ognibene, FP; Parker, MM; Quezado, ZM; Reda, D; Wilson, WH, 1993)
"Seventy-two patients with recurrent or refractory malignant lymphoproliferative diseases were treated with MIME combination chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) and concurrent mesna to prevent urothelial toxicity; 41 patients had high/intermediate-grade non-Hodgkin's lymphoma (NHL), 18 low-grade NHL/chronic lymphocytic leukemia (CLL), and 13 Hodgkin's disease (HD)."	5.07	MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. ( Brincker, H; Mirza, MR, 1991)
"Ifosfamide is an alkylating agent with proven efficacy in the treatment of solid tumours and malignant lymphomas."	4.81	The role of ifosfamide in the treatment of relapsed and refractory lymphoma. ( Bredenfeld, H; Diehl, V; Engert, A; Reiser, M, 2001)
"The alkylating agent ifosfamide, an analog of cyclophosphamide, has demonstrated significant activity in soft tissue sarcoma and testicular carcinoma."	4.77	Ifosfamide. ( Baker, LH; Zalupski, M, 1988)
"Contemporary data of peripheral T-cell lymphoma (PTCL) and natural-killer/T-cell lymphoma (NKTL) patients treated with ifosfamide, carboplatin and etoposide (ICE) are limited."	4.12	Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy. ( Chan, EHL; Chan, JYS; Chang, EWY; Chee, YL; de Mel, S; Diong, C; Farid, M; Goh, AZK; Goh, YT; Grigoropoulos, NF; Jeyasekharan, A; Khoo, LP; Lee, J; Lee, YS; Lim, C; Lim, ST; Liu, X; Nagarajan, C; Poon, E; Poon, M; Quek, R; Somasundaram, N; Tan, D; Tang, T; Tao, M; Tay, T; Yang, VSW, 2022)
"A total of 73 patients who received 187 total cycles of ifosfamide, carboplatin, and etoposide chemotherapy for the treatment of lymphoma were included in this study."	3.96	Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy. ( Ayarza, M; Clark, SM; Hairston, A; Lentz, KL; Liu, B; Morgan, KP; Wind, LS, 2020)
"A retrospective study of sarcoma and lymphoma patients receiving ifosfamide chemotherapy was performed at the participating institutions."	3.81	An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. ( Butrynski, J; Cirrone, F; Feng, Y; Fisher, DC; Harris, C; McDonnell, AM; Neuberg, D; Szabatura, AH; Voit, D, 2015)
"ICE/R-ICE (ifosfamide, carboplatin, and etoposide without or with rituximab) chemotherapy followed by autologous stem cell transplantation is an established regimen in refractory/relapsed lymphoma."	3.80	Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation. ( Bai, L; Greenwood, M; Kerridge, I; Ma, CK; Reid, C; Ward, C; Wong, K; Xia, W, 2014)
"Patients with lymphoma underwent chemomobilization with ifosfamide and etoposide with or without rituximab (IE ± R)."	3.77	Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. ( Balzer, RJ; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Khouri, I; McMannis, J; Popat, U; Qazilbash, M; Rhodes, B; Smith, V; Thompson, R; Walters, K, 2011)
"In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)."	3.77	Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. ( Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T, 2011)
"We evaluated response, progression-free survival (PFS), overall survival (OS), relapse patterns and long-term toxicity of intraocular lymphoma (IOL) patients treated with ifosfamide (IFO) or trofosfamide (TRO)."	3.75	Ifosfamide or trofosfamide in patients with intraocular lymphoma. ( Bechrakis, NE; Fischer, L; Jahnke, K; Korfel, A; Kraemer, DF; Thiel, E; Willerding, G, 2009)
"Chemotherapy-susceptive multiple myeloma (MM) has an indication for high-dose melphalan (HDM) followed by autologous stem cell transplantation (auto-SCT)."	3.74	[Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation]. ( Aoyama, T; Imataki, O; Kawakami, K; Tamai, Y, 2007)
"Two commonly used chemotherapy regimens for lymphoma salvage therapy were compared: ICE (ifosphamide, carboplatin and etoposide) +/- rituximab and IVE (ifosfamide, epirubicin and etoposide) +/- rituximab, for their efficacy in mobilising peripheral blood stem cells for autologous transplantation."	3.74	IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. ( Bishton, MJ; Fox, CP; Haynes, AP; McMillan, AK; Russell, NH, 2008)
" This study describes a 36-year-old woman with primary refractory T-cell lymphoma, who developed central nervous system toxicity due to treatment with intrathecal methotrexate and intravenous ifosfamide, idarubicine and etoposide given as a salvage regimen."	3.73	Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma. ( Abali, H; Dizdar, O; Erdem, I; Eren, OO; Erman, M; Karadağ, O; Türker, A; Uluç, K; Yilmaz, A, 2005)
"A three-drug combination of ifosfamide, epirubicin and etoposide (IEV) was used to treat 62 patients with relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL; n=51) or Hodgkin's disease (HD; n=11)."	3.71	Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. ( Alinari, L; Baccarani, M; Bonifazi, F; Gabriele, A; Molinari, AL; Salvucci, M; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zuffa, E, 2002)
"In three new approved indications (non Hodgkin's lymphoma, Hodgkin's lymphoma and acute lymphoblastic leukaemia) and in three previously existing indications (ovarian cancer, soft tissue sarcomas and osteogenic sarcomas), non comparative trials show that ifosfamide can induce tumour regression in patients who relapse after a first course of chemotherapy (sometimes containing cyclophosphamide)."	3.70	Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness. ( , 1998)
"An intensive brief chemotherapy and radiotherapy regimen including high doses of cyclo-phosphamide (5 g/m2), etoposide (1 g/m2), epirubicin (180 mg/m2), and ifosfamide (5 g/m2) administered in a period of 30 days followed by involved field radiotherapy to sites of initial bulky disease was administered to 46 untreated patients with high-intermedium and high-risk malignant lymphoma."	3.69	Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma. ( Avilés, A; Delgado, S; Díaz-Maqueo, JC; García, EL; Guzmán, R; Nambo, MJ, 1996)
"Twelve patients with relapsed or refractory malignant lymphoma were treated with IMV-triple P regimen consisting of ifosfamide (IFM), mitoxantrone (MIT), vindesine (VDS), pepleomycin (PEP), procarbazine (PCZ) and prednisolone (PDN)."	3.68	[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma]. ( Arai, N; Hara, A; Shirai, T; Umeda, M, 1991)
"Thirty-seven patients with malignant lymphoma were treated with mitoxantrone, ifosfamide, vindesine, and prednisolone."	3.68	Therapy with mitoxantrone, ifosfamide, vindesine, and prednisolone for malignant lymphoma with adjustable doses and timing of courses. ( Furukawa, Y; Hiyoshi, M; Im, T; Inoue, T; Kishida, T; Okuda, K; Park, K; Sasaki, A; Tatsumi, N; Yamane, T, 1991)
"Thirty adult patients with relapsed or refractory malignant lymphoma underwent a Phase I-II trial of salvage chemotherapy combining methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI protocol)."	3.68	Salvage therapy with methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI) for recurrent or refractory lymphoma. ( Baume, D; Carde, P; Droz, JP; Gilles, E; Hayat, M; Moran, A; Ostronoff, M; Pico, JL; Zambon, E, 1990)
"Twenty patients with refractory malignant lymphoma were treated with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) as salvage chemotherapy."	3.67	[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma]. ( Goto, S; Hotta, T; Ichikawa, A; Inoue, C; Murate, T; Nagura, E; Ninomiya, N; Ohnishi, K; Tsushita, K; Utsumi, M, 1989)
"From 1981 to 1983, 208 patients with recurrent or refractory lymphoma were treated with methylglyoxal-bis-guanylhydrazone (methyl-GAG), ifosfamide, methotrexate, etoposide (MIME)."	3.67	Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. ( Cabanillas, F; Hagemeister, FB; Jagannath, S; McLaughlin, P; Redman, JR; Rodriguez, MA; Swan, F; Velasquez, WS, 1988)
"Eighteen patients with high-grade malignant lymphoma were treated with ifosfamide-VP16213 combinations after failing to respond completely or after relapsing on CHOP-like therapy."	3.67	Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma. ( Huijgens, PC; Ossenkoppele, GJ; Reijneke, RM; Thomas, LL; van der Lelie, J; Wijngaarden, MJ, 1988)
"Between 1983 and 1985, we conducted a phase II clinical trial using VP-16, ifosfamide, and cisplatin (VIP) in patients with refractory lymphoma."	3.67	Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. ( Greist, A; Hoffman, R; Kubilis, PS; Loehrer, PJ; Nichols, CR, 1988)
"The result of a combination consisting of ifosfamide and etoposide was evaluated in 57 patients suffering from non-Hodgkin's lymphoma (NHL) who had relapsed or were resistant to adriamycin-containing combinations."	3.67	Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma. ( Cavallin-Ståhl, E; Hagberg, H; Lind, J, 1986)
"Eighteen patients with advanced non-Hodgkin's lymphoma other than the diffuse histiocytic type were treated with a combination of adriamycin, vincristine, ifosfamide and prednisolone (AVIP)."	3.66	Combination chemotherapy of advanced non-Hodgkin's lymphoma with adriamycin, vincristine, ifosfamide and prednisolone (AVIP): a preliminary report. ( Hayashi, K; Kimura, I; Nishihara, R; Ohnoshi, T; Oka, A; Sando, Y; Sato, M; Tanaka, T; Ueoka, H; Yasuoka, M, 1982)
"Twenty patients with malignant lymphomas refractory to prior combination chemotherapy were treated with ifosfamide (40 mg/kg/day i."	3.66	Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy. ( Bremer, K; Niederle, N; Scheulen, ME; Seeber, S, 1983)
"Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed."	2.73	Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007)
"Seven of the 15 patients with malignant lymphoma responded."	2.64	Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. ( Bodey, GP; Freireich, EJ; Keating, MJ; McCredie, KB; Rodriguez, V; Valdivieso, M, 1978)
"Ifosfamide (IFO) is a widely used antitumor agent, requiring activation to isophosphoramide mustard (IPM) for DNA alkylation."	2.43	Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. ( Lokiec, F, 2006)
"Ifosfamide is an active agent as part of combination therapy for patients with both indolent and aggressive relapsed lymphomas, and has also been used in high-dose therapy regimens followed by stem cell or bone marrow rescue."	2.40	The role of ifosfamide in the treatment of lymphomas. ( Hagemeister, FB, 1999)
"BACKGROUND The aim of this study was to compare nutrition-related adverse events and clinical outcomes of ifosfamide, carboplatin, and etoposide regimen (ICE therapy) and ranimustine, carboplatin, etoposide, and cyclophosphamide regimen (MCEC therapy) instituted as pretreatment for autologous peripheral blood stem cell transplantation."	1.48	Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem C ( Aoyama, T; Arai, H; Ikeda, T; Imataki, O; Ishide, K; Katsumata, N; Kume, T; Mori, M; Shiozaki, H, 2018)
"Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD)."	1.33	IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. ( Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A, 2005)
"A 42-year-old woman with refractory ulcerative colitis (UC) developed ascites, pleural effusion, pretibial edema and severe anemia."	1.32	Association of intestinal malignant lymphoma and ulcerative colitis. ( Hanioka, K; Maeda, A; Matsushita, A; Nagai, K; Sugimoto, N; Takahashi, T; Watanabe, N, 2003)
"Primary hepatic lymphoma is rare malignancy."	1.31	Cure in a case of primary hepatic lymphoma. ( Aggarwal, S; Arora, A; Bhalla, S; Murthy, SA; Singh, B; Vohra, R, 2000)
"Recently, specific chromosomal abnormalities have been described for several solid tumor malignancies."	1.29	Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. ( Bosl, GJ; Chaganti, RS; Mazumdar, M; Motzer, RJ; Reuter, VE; Rodriguez, E, 1995)
"Eight patients had low-grade non-Hodgkin's lymphoma (NHL), 28 had high-grade NHL, and 11 patients had Hodgkin's disease."	1.28	Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. ( Anders, CH; Moritz, T; Nagel-Hiemke, M; Niederle, N; Nowrousian, MR; Schmidt, CG; Seeber, S, 1991)
"Fifty-six patients with malignant lymphoma of aggressive histologic type (51 large cell, three diffuse undifferentiated, and two nodular mixed) were treated with three non-cross-resistant combination chemotherapy regimens that were introduced sequentially according to the response to therapy."	1.27	Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. ( Bodey, GP; Burgess, MA; Cabanillas, F; Freireich, EJ, 1983)
"Ifosfamide was given to 61 patients with malignant solid tumors diagnosed before the age of 21 years."	1.27	Phase II trial of ifosfamide in children with malignant solid tumors. ( Douglass, EC; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA, 1987)

Research

Studies (113)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Ability to Proceed to Peripheral Blood Stem Cell Collection Following Treatment

Efficacy (Response Rate) of Vorinostat Combined With RICE Chemotherapy

Maximum Tolerated Dose of Vorinostat

Safety and Toxicity According to CTCAE v3.0

Timeframe	Studies, this research(%)	All Research%
pre-1990	27 (23.89)	18.7374
1990's	30 (26.55)	18.2507
2000's	40 (35.40)	29.6817
2010's	12 (10.62)	24.3611
2020's	4 (3.54)	2.80

Authors	Studies
Tay, T	1
Somasundaram, N	1
Lim, C	1
Khoo, LP	1
Goh, AZK	1
Lee, YS	1
Liu, X	1
Tao, M	1
Quek, R	1
Farid, M	1
Poon, E	1
Chan, JYS	1
Chang, EWY	1
Yang, VSW	1
Goh, YT	1
Tan, D	1
Diong, C	1
Grigoropoulos, NF	1
Nagarajan, C	1
Poon, M	1
de Mel, S	1
Jeyasekharan, A	1
Chan, EHL	1
Lee, J	2
Chee, YL	1
Lim, ST	1
Tang, T	1
Stamatoullas, A	1
Ghesquières, H	1
Feugier, P	1
André, M	1
Le Bras, F	1
Gac, AC	1
Borel, C	1
Gastinne, T	1
Quittet, P	1
Morschhauser, F	1
Ribrag, V	1
Guidez, S	1
Nicolas-Virelizier, E	1
Berriolo-Riedinger, A	1
Vander Borght, T	1
Edeline, V	1
Brice, P	1
Ostrowska, B	1
Domanska-Czyz, K	1
Romejko-Jarosinska, J	1
Osowiecki, M	1
Targonski, L	1
Poplawska, L	1
Konecki, R	1
Kotarska, M	1
Szymanski, M	1
Borawska, A	1
Swierkowska, M	1
Dabrowska-Iwanicka, A	1
Druzd-Sitek, A	1
Paszkiewicz-Kozik, E	1
Mroz-Zycinska, E	1
Tajer, J	1
Wojciechowska-Lampka, E	1
Osiadacz, W	1
Rymkiewicz, G	1
Lapinska, G	1
Wojewodzka-Mirocha, M	1
Michalski, W	1
Walewski, J	1
Teepen, JC	1
van Leeuwen, FE	1
Tissing, WJ	1
van Dulmen-den Broeder, E	1
van den Heuvel-Eibrink, MM	1
van der Pal, HJ	1
Loonen, JJ	1
Bresters, D	1
Versluys, B	1
Neggers, SJCMM	1
Jaspers, MWM	1
Hauptmann, M	1
van der Heiden-van der Loo, M	1
Visser, O	1
Kremer, LCM	1
Ronckers, CM	1
Aoyama, T	2
Imataki, O	2
Arai, H	1
Kume, T	1
Shiozaki, H	1
Katsumata, N	1
Mori, M	1
Ishide, K	1
Ikeda, T	1
Reid, EG	1
Looney, D	1
Maldarelli, F	1
Noy, A	1
Henry, D	1
Aboulafia, D	1
Ramos, JC	1
Sparano, J	1
Ambinder, RF	1
Cesarman, E	1
Yahyaei, S	1
Mitsuyasu, R	1
Wachsman, W	1
Lentz, KL	1
Clark, SM	1
Ayarza, M	1
Liu, B	1
Morgan, KP	1
Wind, LS	1
Hairston, A	1
Szabatura, AH	1
Cirrone, F	1
Harris, C	1
McDonnell, AM	1
Feng, Y	1
Voit, D	1
Neuberg, D	1
Butrynski, J	1
Fisher, DC	1
Xia, W	1
Ma, CK	1
Reid, C	1
Bai, L	1
Wong, K	1
Kerridge, I	1
Ward, C	1
Greenwood, M	1
Zhou, P	1
Liu, P	1
Zhou, SY	1
He, XH	1
Han, XH	1
Qin, Y	1
Yang, S	1
Zhang, CG	1
Gui, L	1
Yao, JR	1
Zhao, LY	1
Zhang, SX	1
Sun, Y	1
Shi, YK	1
Ramirez, MD	1
Mertens, AC	1
Esiashvili, N	1
Meacham, LR	1
Wasilewski-Masker, K	1
Fischer, L	4
Korfel, A	5
Kiewe, P	2
Neumann, M	1
Jahnke, K	4
Thiel, E	5
Bechrakis, NE	2
Willerding, G	1
Kraemer, DF	1
Pfeiffer, S	1
Volk, HD	1
Cakiroglu, H	1
Widmann, T	1
Cabanillas, F	11
Martus, P	1
Kanz, L	2
Griesinger, F	1
Rauch, M	1
Röth, A	1
Hertenstein, B	1
von Toll, T	1
Hundsberger, T	1
Mergenthaler, HG	1
Leithäuser, M	1
Birnbaum, T	1
Herrlinger, U	1
Plasswilm, L	1
Nägele, T	1
Pietsch, T	1
Bamberg, M	1
Weller, M	1
Hosing, C	1
Smith, V	1
Rhodes, B	1
Walters, K	1
Thompson, R	1
Qazilbash, M	1
Khouri, I	1
de Lima, M	1
Balzer, RJ	1
McMannis, J	1
Champlin, R	1
Giralt, S	1
Popat, U	1
Motomura, K	1
Natsume, A	1
Fujii, M	1
Ito, M	1
Momota, H	1
Wakabayashi, T	2
Budde, LE	1
Zhang, MM	1
Shustov, AR	1
Pagel, JM	1
Gooley, TA	1
Oliveira, GR	1
Chen, TL	1
Knudsen, NL	1
Roden, JE	1
Kammerer, BE	1
Frayo, SL	1
Warr, TA	1
Boyd, TE	1
Press, OW	1
Gopal, AK	1
Zinzani, PL	1
Tani, M	1
Molinari, AL	1
Stefoni, V	1
Zuffa, E	1
Alinari, L	1
Gabriele, A	1
Bonifazi, F	1
Salvucci, M	1
Tura, S	1
Baccarani, M	1
Emmanouilides, C	1
Lill, M	1
Telatar, M	1
Rosenfelt, F	1
Grody, W	1
Territo, M	1
Rosen, P	1
Pels, H	1
Schmidt-Wolf, IG	1
Glasmacher, A	1
Schulz, H	1
Engert, A	2
Diehl, V	3
Zellner, A	1
Schackert, G	1
Reichmann, H	1
Kroschinsky, F	1
Vogt-Schaden, M	1
Egerer, G	1
Bode, U	1
Schaller, C	1
Deckert, M	1
Fimmers, R	1
Helmstaedter, C	1
Atasoy, A	1
Klockgether, T	1
Schlegel, U	1
Watanabe, N	1
Sugimoto, N	1
Matsushita, A	1
Maeda, A	1
Nagai, K	1
Hanioka, K	1
Takahashi, T	1
Jerkeman, M	1
Leppä, S	1
Kvaløy, S	2
Holte, H	2
Fridrik, MA	1
Hausmaninger, H	1
Linkesch, W	1
Greil, R	1
Krieger, O	1
Baldinger, C	1
Klocker, J	1
Pont, J	1
Oberaigner, W	1
Cairo, MS	1
Davenport, V	1
Bessmertny, O	1
Goldman, SC	1
Berg, SL	1
Kreissman, SG	1
Laver, J	1
Shen, V	1
Secola, R	1
van de Ven, C	1
Reaman, GH	1
Biagi, JJ	1
Herbert, KE	1
Smith, C	1
Abdi, E	1
Leahy, M	1
Falkson, C	1
Wolf, M	1
Januszewicz, H	1
Seymour, JF	1
Richards, K	1
Matthews, JP	1
Dale, B	1
Prince, HM	1
Keaney, CM	1
Springate, JE	1
Abali, H	2
Oyan, B	1
Koc, Y	1
Kars, A	1
Barista, I	1
Uner, A	1
Turker, A	2
Demirkazik, F	1
Tekin, F	1
Tekuzman, G	1
Kansu, E	1
Komm, J	1
Stein, H	1
Coupland, SE	1
Cho, JH	1
Kim, HS	1
Ko, YH	1
Park, CS	1
Eren, OO	1
Dizdar, O	1
Karadağ, O	1
Erman, M	1
Yilmaz, A	1
Uluç, K	1
Erdem, I	1
Lokiec, F	1
Colombat, P	1
Lemevel, A	1
Bertrand, P	1
Delwail, V	1
Rachieru, P	1
Brion, A	1
Berthou, C	1
Bay, JO	1
Delepine, R	1
Desablens, B	1
Camilleri-Broët, S	1
Linassier, C	1
Lamy, T	1
Schütt, P	1
Passon, J	1
Ebeling, P	1
Welt, A	1
Müller, S	1
Metz, K	1
Moritz, T	2
Seeber, S	3
Nowrousian, MR	2
Todisco, E	1
Castagna, L	2
Sarina, B	2
Mazza, R	1
Magagnoli, M	2
Balzarotti, M	2
Nozza, A	2
Siracusano, L	2
Timofeeva, I	2
Anastasia, A	1
Demarco, M	1
Santoro, A	2
Tamai, Y	1
Kawakami, K	1
Vives, S	1
Sancho, JM	1
Juncà, J	1
Grifols, JR	1
Morgades, M	1
Ribera, JM	1
Fox, CP	1
McMillan, AK	1
Bishton, MJ	1
Haynes, AP	2
Russell, NH	2
Takeuchi, S	1
Akahoshi, Y	1
Kasai, C	1
Nishimoto, Y	1
Burgess, MA	1
Bodey, GP	5
Freireich, EJ	4
Kimura, I	4
Scheulen, ME	1
Bremer, K	1
Niederle, N	2
Retsas, S	1
Burkert, H	1
Ohnoshi, T	2
Oka, A	2
Hayashi, K	2
Ueoka, H	1
Sato, M	2
Nishihara, R	2
Yasuoka, M	1
Sando, Y	1
Tanaka, T	2
Hagemeister, FB	9
Rodriguez, V	2
Nakata, Y	1
Sezaki, T	1
Hirano, M	2
Haim, N	1
Ben-Shahar, M	1
Epelbaum, R	1
Brugger, W	1
Möcklin, W	1
Heimfeld, S	1
Berenson, RJ	1
Mertelsmann, R	1
Motzer, RJ	1
Rodriguez, E	1
Reuter, VE	1
Bosl, GJ	1
Mazumdar, M	1
Chaganti, RS	1
Romaguera, JE	2
Rodriguez, MA	4
McLaughlin, P	4
Swan, F	3
Moore, DF	1
Sarris, AH	1
Younes, A	1
Hill, D	1
Cerny, T	1
Denzlinger, C	1
Walther, J	1
Wilmanns, W	1
Gerhartz, HH	1
Quezado, ZM	1
Wilson, WH	2
Cunnion, RE	1
Parker, MM	1
Reda, D	1
Bryant, G	2
Ognibene, FP	1
Cabanillas, FC	1
Velasquez, W	1
Avilés, A	1
Guzmán, R	1
Delgado, S	1
Nambo, MJ	1
García, EL	1
Díaz-Maqueo, JC	1
McQuaker, IG	1
Stainer, C	1
Anderson, S	1
Okamoto, M	2
Lister, J	1
Rybka, WB	1
Donnenberg, AD	1
deMagalhaes-Silverman, M	1
Pincus, SM	1
Bloom, EJ	1
Elder, EM	1
Ball, ED	1
Whiteside, TL	1
Mayer, J	2
Korístek, Z	2
Vásová, I	2
Vorlícek, J	2
Vodvárka, P	2
Pichler, R	1
Hatzl-Griesenhofer, M	1
Huber, H	1
Wimmer, G	1
Wahl, G	1
Maschek, W	1
Pfeilstöcker, M	1
Karlic, H	1
Salamon, J	1
Mühlberger, H	1
Pavlova, B	1
Strobl, H	1
Pittermann, E	1
Heinz, R	1
Takasu, S	1
Kajita, Y	1
Hatano, N	1
Hatano, H	1
Usui, T	1
Kinoshita, T	1
Yoshida, J	1
Aurlien, E	1
Jakobsen, E	1
Rusten, LS	1
Kvalheim, G	1
Proctor, SJ	1
Taylor, PR	1
Angus, B	1
Wood, K	1
Lennard, AL	1
Lucraft, H	1
Carey, PJ	1
Stark, A	1
Iqbal, A	1
Haynes, A	1
Russel, N	1
Leonard, RC	1
Culligan, D	1
Conn, J	1
Jackson, GH	1
Navrátil, M	1
Klabusay, M	1
Doubek, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation[NCT02686346]	Phase 1/Phase 2	53 participants (Actual)	Interventional	2016-03-31	Completed
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma[NCT00598169]	Phase 1	23 participants (Actual)	Interventional	2007-11-30	Completed
Phase IV Study on the Role of Whole Brain Irradiation in Primary CNS Lymphoma (PCNSL) After High-dose Methotrexate[NCT00153530]	Phase 4	604 participants (Anticipated)	Interventional	2000-05-31	Completed
A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655]	Phase 2	51 participants (Anticipated)	Interventional	2020-09-01	Not yet recruiting
High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841]	Phase 3	250 participants (Anticipated)	Interventional	2014-07-31	Recruiting
A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma[NCT00601718]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2007-12-31	Completed
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]	Phase 2	11 participants (Actual)	Interventional	2010-10-14	Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
Open-labeled, Multicenter, Phase I/II Study of Imatinib Combined With ESHAP as Salvage Therapy in Relapsed/Refractory Non-Hodgkin's Lymphoma[NCT02431403]	Phase 1/Phase 2	94 participants (Anticipated)	Interventional	2015-02-28	Recruiting
Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467]	Phase 2	150 participants (Actual)	Interventional	2006-08-31	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy	20

Intervention	Participants (Count of Participants)
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy	19

Intervention	mg twice daily X 5 days (Number)
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy	500

Common dose limiting toxicities. (NCT00601718)
Timeframe: 3-5 weeks post end of treatment

Safest Dose of Temozolomide for the DRBEAT Regimen

Intervention	Participants (Count of Participants)
	Infection	Hypokalemia	Transaminitis	Grade 3 related gastrointestinal toxicity
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy	2	2	2	9

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

One-year Progression-free Survival and Overall Survival

Intervention	dose in mg/m^2 (Number)
DRBEAT Regimen	773.25

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

Intervention	Days (Median)
	Progression Free Survival	Overall Survival
DRBEAT Regimen	132	564

Article	Year
Cancer and the kidney. Adolescent medicine clinics, 2005, Volume: 16, Issue:1 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carcinoma, Renal Cell; Comorbi	2005
Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 4 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Humans; Ifosfamide; Lymphoma; N	2006
Ifosfamide: European perspective. Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1 Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat	1982
[Malignant lymphoma]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1994, Mar-10, Volume: 83, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide;	1994
The role of ifosfamide in the treatment of lymphomas. Leukemia & lymphoma, 1999, Volume: 34, Issue:5-6 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Ste	1999
The role of ifosfamide in the treatment of relapsed and refractory lymphoma. European journal of haematology. Supplementum, 2001, Volume: 64 Topics: Antineoplastic Agents, Alkylating; Disease-Free Survival; Humans; Ifosfamide; Lymphoma; Recurrence;	2001
Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience. European journal of haematology. Supplementum, 2001, Volume: 64 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hematopoietic Stem Cell T	2001
[Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc	2001
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer chemotherapy and pharmacology, 2002, Volume: 49 Suppl 1 Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin	2002
Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States. Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 12 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Chil	1992
Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia. Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Leukemia; Lymphoma; Neopl	1990
Experience with ifosfamide combinations in malignant lymphomas. Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma; Methotrexat	1989
Ifosfamide. Journal of the National Cancer Institute, 1988, Jun-15, Volume: 80, Issue:8 Topics: Breast Neoplasms; Drug Evaluation, Preclinical; Female; Humans; Ifosfamide; Lung Neoplasms; Lymphoma	1988

Article	Year
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. Leukemia & lymphoma, 2022, Volume: 63, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carboplatin; Etoposide; Hodgkin	2022
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. Blood advances, 2018, 12-26, Volume: 2, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; APOBEC-3G Deaminase; Bortezomib; Carbop	2018
Yield of Urinalysis Screening in Pediatric Cancer Survivors. Pediatric blood & cancer, 2016, Volume: 63, Issue:5 Topics: Adolescent; Adult; Child; Child, Preschool; Databases, Factual; Female; Follow-Up Studies; Glycosuri	2016
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. The Lancet. Oncology, 2010, Volume: 11, Issue:11 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervo	2010
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. The Lancet. Oncology, 2010, Volume: 11, Issue:11 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervo	2010
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. The Lancet. Oncology, 2010, Volume: 11, Issue:11 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervo	2010
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. The Lancet. Oncology, 2010, Volume: 11, Issue:11 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervo	2010
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. British journal of haematology, 2013, Volume: 161, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;	2013
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma. Clinical lymphoma, 2002, Volume: 3, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigen	2002
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-15, Volume: 21, Issue:24 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo	2003
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. European journal of haematology, 2004, Volume: 73, Issue:3 Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Pr	2004
Long-term results of dose density therapy in patients with aggressive lymphoma. Annals of hematology, 2005, Volume: 84, Issue:4 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide;	2005
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. British journal of haematology, 2005, Volume: 128, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch	2005
A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leukemia & lymphoma, 2005, Volume: 46, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Administ	2005
Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2006, Volume: 244, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclophosphamide	2006
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone marrow transplantation, 2006, Volume: 38, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;	2006
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone marrow transplantation, 2006, Volume: 38, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;	2006
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone marrow transplantation, 2006, Volume: 38, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;	2006
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone marrow transplantation, 2006, Volume: 38, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;	2006
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. European journal of haematology, 2007, Volume: 78, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Thera	2007
CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. European journal of haematology, 2007, Volume: 78, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Muri	2007
Ifosfamide: European perspective. Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1 Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat	1982
Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cispl	1995
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Investigational new drugs, 1994, Volume: 12, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati	1994
Interleukin-3 enhances the endogenous leukotriene production. Blood, 1993, May-01, Volume: 81, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Humans; Ifosfamide; Interleuk	1993
High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Annals of internal medicine, 1993, Jan-01, Volume: 118, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Bone	1993
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans;	1995
[Long-term follow up of aggressive lymphoma patients treated with CAMBO-VIP--clinical significance of a residual mass after otherwise successful chemotherapy]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1998, Volume: 39, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit	1998
Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:6 Topics: Adoptive Transfer; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Busulfan; Cells, Cultured;	1995
[Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma]. No shinkei geka. Neurological surgery, 2000, Volume: 28, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplati	2000
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. European journal of haematology. Supplementum, 2001, Volume: 64 Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component R	2001
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. European journal of haematology. Supplementum, 2001, Volume: 64 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Ho	2001
Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. European journal of haematology. Supplementum, 2001, Volume: 64 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Graft Survival	2001
Effective progenitor cell mobilization in lymphoproliferative disorders using ifosfamide, epirubicin and etoposide (IEV). European journal of haematology. Supplementum, 2001, Volume: 64 Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etopo	2001
Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. British journal of haematology, 2001, Volume: 114, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chi-	2001
Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients. Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:2 Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplati	2001
Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone marrow transplantation, 2001, Volume: 28, Issue:10 Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Female; Granulocyte Col	2001
Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer treatment reports, 1978, Volume: 62, Issue:4 Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Cyclophosphamide; Drug Resistance; Femal	1978
Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati	1992
MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. Acta oncologica (Stockholm, Sweden), 1991, Volume: 30, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Hodgkin Disease; Humans; Ifo	1991
Treatment of relapsed non-Hodgkin's lymphoma with a combination of hydroxyurea, ifosfamide, and etoposide. Cancer treatment reports, 1985, Volume: 69, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; E	1985

Article	Year
Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy. Cancer reports (Hoboken, N.J.), 2022, Volume: 5, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Lymphoma	2022
Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience. British journal of haematology, 2023, Volume: 201, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; COVID-19; Cytarabi	2023
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-10, Volume: 35, Issue:20 Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla	2017
Comparison of Nutrition-Related Adverse Events and Clinical Outcomes Between ICE (Ifosfamide, Carboplatin, and Etoposide) and MCEC (Ranimustine, Carboplatin, Etoposide, and Cyclophosphamide) Therapies as Pretreatment for Autologous Peripheral Blood Stem C Medical science monitor basic research, 2018, Feb-05, Volume: 24 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Energy Intake;	2018
Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cohort Studies; Etoposi	2020
An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:3 Topics: Antineoplastic Agents, Alkylating; Brain Diseases; Cancer Care Facilities; Cisplatin; Female; Humans	2015
Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation. Journal of clinical apheresis, 2014, Volume: 29, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;	2014
Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas. Chinese medical journal, 2015, Sep-20, Volume: 128, Issue:18 Topics: Adolescent; Adult; Antineoplastic Agents; Carboplatin; Child; Cisplatin; Etoposide; Female; Hematopo	2015
Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Annals of hematology, 2009, Volume: 88, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst	2009
Ifosfamide or trofosfamide in patients with intraocular lymphoma. Journal of neuro-oncology, 2009, Volume: 93, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cyclophosphamide; Eye Neoplasms; Follow-	2009
CXCL13 and CXCL12 in central nervous system lymphoma patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C	2009
How important is whole brain radiotherapy for treatment of primary CNS lymphoma? The Lancet. Oncology, 2010, Volume: 11, Issue:11 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Sys	2010
Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion, 2011, Volume: 51, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclo	2011
Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leukemia & lymphoma, 2011, Volume: 52, Issue:11 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous Sy	2011
Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica, 2002, Volume: 87, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb	2002
Future perspectives in the treatment of malignant lymphomas: focus on ifosfamide. Proceedings of a symposium. Cap Ferrat, France. October 17, 2002. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14 Suppl 1 Topics: Antineoplastic Agents, Alkylating; Forecasting; Humans; Ifosfamide; Lymphoma	2003
Association of intestinal malignant lymphoma and ulcerative colitis. Internal medicine (Tokyo, Japan), 2003, Volume: 42, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Colitis, Ulcerative; Colonoscopy;	2003
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. American journal of clinical oncology, 2005, Volume: 28, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; F	2005
Epstein-Barr virus infected natural killer cell lymphoma in a patient with hypersensitivity to mosquito bite. The Journal of infection, 2006, Volume: 52, Issue:6 Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Culicidae; Epstein-Barr Viru	2006
Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma. Leukemia & lymphoma, 2005, Volume: 46, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Etoposide; Fatal Outcome; Female; Hem	2005
[Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Ag	2007
[High-dose ifosfamide and etoposide regimen as salvage and mobilization therapy for patients with lymphoma]. Medicina clinica, 2008, Feb-16, Volume: 130, Issue:5 Topics: Adult; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma; Male;	2008
IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. British journal of haematology, 2008, Volume: 141, Issue:2 Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carboplatin	2008
[Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors]. Gan no rinsho. Japan journal of cancer clinics, 1984, Volume: 30, Issue:9 Suppl Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide;	1984
Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. The American journal of medicine, 1983, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclo	1983
[Chemotherapy in advanced non-Hodgkin's lymphoma: follow-up studies]. Nihon rinsho. Japanese journal of clinical medicine, 1983, Volume: 41, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici	1983
Long-term survivors of malignant lymphoma patients treated with combination chemotherapy: a retrospective analysis. Japanese journal of medicine, 1984, Volume: 23, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Hodgkin Di	1984
Treatment of refractory malignant lymphomas with ifosfamide/etoposide combination chemotherapy. Cancer treatment reviews, 1983, Volume: 10 Suppl A Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Humans; Ifosfamide; Lym	1983
Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy. Cancer treatment reviews, 1983, Volume: 10 Suppl A Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Ifosfamide;	1983
Combination chemotherapy of advanced non-Hodgkin's lymphoma with adriamycin, vincristine, ifosfamide and prednisolone (AVIP): a preliminary report. Acta medica Okayama, 1982, Volume: 36, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Huma	1982
IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood, 1982, Volume: 60, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cyclophosphamide; Drug	1982
Studies with ifosfamide in patients with malignant lymphoma. Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1 Topics: Antineoplastic Agents; Bone Marrow; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; He	1982
[Clinical efficacy of four-drug combination treatment of adriamycin, vincristine, ifosfamide, and prednisolone for patients with malignant lymphoma, especially relapsed or refractory types (author's transl)]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1980, Volume: 21, Issue:6 Topics: Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Humans; Ifosfamide; Lymphoma; Prednisolone	1980
Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood, 1993, May-15, Volume: 81, Issue:10 Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Divisi	1993
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:1 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Carcinoma	1995
MINE-ESHAP salvage therapy for recurrent and refractory lymphomas. Seminars in hematology, 1994, Volume: 31, Issue:2 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide	1994
High dose ifosfamide with mesna uroprotection. Pathologie-biologie, 1993, Volume: 41, Issue:1 Topics: Drug Therapy, Combination; Humans; Ifosfamide; Lymphoma; Mesna; Urologic Diseases	1993
Intensive brief chemotherapy with hematopoietic growth factors as hematological support and adjuvant radiotherapy improve the prognosis in aggressive malignant lymphoma. American journal of hematology, 1996, Volume: 52, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha	1996
Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. British journal of haematology, 1997, Volume: 98, Issue:1 Topics: Adult; Aged; Cyclophosphamide; Drug Combinations; Epirubicin; Etoposide; Female; Granulocyte Colony-	1997
Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Bone marrow transplantation, 1999, Volume: 23, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etopos	1999
Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness. Prescrire international, 1998, Volume: 7, Issue:34 Topics: Adult; Antineoplastic Agents, Alkylating; Breast Neoplasms; Child; Clinical Trials as Topic; Cycloph	1998
[Primary lymphoma of the thyroid with contralateral recurrence--case report]. Wiener klinische Wochenschrift, 1999, Apr-23, Volume: 111, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Citrates; Cyclophosphamide; Dexamethasone; Epirubici	1999
Hematopoietic recovery after IEV chemotherapy for malignant lymphoma followed by different cytokines can be monitored by analysis of Galpha 16 and CD34. American journal of hematology, 2000, Volume: 64, Issue:3 Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Epirubicin; Etopos	2000
The role of ifosfamide in cytoreduction, stem cell mobilization and high-dose therapy in relapsed/refractory malignant lymphomas. European journal of haematology. Supplementum, 2001, Volume: 64 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Ste	2001
ICE--an efficient drug combination for stem cell mobilization and high-dose treatment of malignant lymphoma. European journal of haematology. Supplementum, 2001, Volume: 64 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Etoposide; Hema	2001
Cure in a case of primary hepatic lymphoma. Indian journal of cancer, 2000, Volume: 37, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Hum	2000
The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB x NZW) mice. II. Emergence of tumors in young animals treated with azathioprine and ifosfamide, including a histologic assessment of the neoplasms. Arzneimittel-Forschung, 1979, Volume: 29, Issue:4 Topics: Animals; Azathioprine; Carcinogens; Carcinoma; Cyclophosphamide; Female; Hyperplasia; Ifosfamide; Ly	1979
In vivo perturbation of human marrow cell cycle progression by ifosfamide. Cancer research, 1978, Volume: 38, Issue:8 Topics: Bone Marrow; Cell Cycle; Cyclophosphamide; DNA, Neoplasm; Erythroblasts; Humans; Ifosfamide; Kinetic	1978
Report on carcinogenesis bioassay of isophosphamide. American Industrial Hygiene Association journal, 1978, Volume: 39, Issue:6 Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma	1978
[Recent progress in the chemotherapy program and its theoretical background--malignant lymphoma]. Nihon rinsho. Japanese journal of clinical medicine, 1992, Volume: 50, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclo	1992
Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2 Suppl 1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation;	1991
[Salvage chemotherapy with IMV-triple P for relapsed or refractory malignant lymphoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Female; Hea	1991
Experience with salvage regimens at M.D. Anderson Hospital. Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; F	1991
Massively bleeding gastrosplenic fistula following cytostatic chemotherapy of a malignant lymphoma. Journal of clinical gastroenterology, 1991, Volume: 13, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Fistula; Gastric Fistula; Gastroin	1991
Therapy with mitoxantrone, ifosfamide, vindesine, and prednisolone for malignant lymphoma with adjustable doses and timing of courses. Osaka city medical journal, 1991, Volume: 37, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; Ifosfamide; Le	1991
Ifosfamide combinations in lymphoma. Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Humans; Ifosfamide; Lymphoma; Remis	1990
Salvage therapy with methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI) for recurrent or refractory lymphoma. Cancer investigation, 1990, Volume: 8, Issue:1 Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Respo	1990
[Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1989, Volume: 30, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Etoposide; Femal	1989
Ifosfamide-induced renal tubular defects. Cancer, 1989, Feb-15, Volume: 63, Issue:4 Topics: Hematuria; Humans; Hydrogen-Ion Concentration; Ifosfamide; Kidney Diseases; Kidney Tubules; Lymphoma	1989
Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Seminars in hematology, 1988, Volume: 25, Issue:2 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin;	1988
Phase II trial of ifosfamide in children with malignant solid tumors. Cancer treatment reports, 1987, Volume: 71, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Eva	1987
Ifosfamide and VP-16213 combination chemotherapy combined with ablative chemotherapy and autologous marrow transplantation as salvage treatment for malignant lymphoma. European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm	1988
Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. Medical and pediatric oncology, 1988, Volume: 16, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Etoposide; H	1988
Results of MIME salvage regimen for recurrent or refractory lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Etoposide; Humans; Ifosfamide; Lymp	1987
Respiratory distress as primary symptom of relapse in a patient with non-Hodgkin lymphoma. Blut, 1985, Volume: 51, Issue:4 Topics: Aged; Female; Humans; Ifosfamide; Lymphoma; Mandibular Neoplasms; Methotrexate; Prednisolone; Respir	1985
Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma. Scandinavian journal of haematology, 1986, Volume: 36, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma; Methotrexat	1986

ifosfamide and Germinoblastoma